Erasca Inc
ERAS1.405USD
+0.015+1.08%
交易中 （美東）報價延遲15分鐘
397.99M總市值
虧損本益比TTM
關於 Erasca Inc 公司
Erasca, Inc. 是一家臨牀階段精準腫瘤學公司。該公司專注於發現、開發和商業化針對 RAS/MAPK 通路驅動癌症患者的療法。該公司已在行業內組建了全資或控制的以 RAS/MAPK 通路爲重點的管線，該管線專注於與其三種治療策略相一致的模式無關項目：針對 RAS/MAPK 通路中的關鍵上游和下游信號傳導節點；直接針對 RAS；以及針對治療後出現的逃逸途徑。其管線包括三個臨牀階段項目，例如泛 RAF 抑制劑、ERK 抑制劑和中樞神經系統 (CNS) 滲透性 EGFR 抑制劑，以及針對其他關鍵致癌驅動因素的其他發現階段項目。其主要候選產品是納帕非尼，一種泛 RAF 抑制劑，可用於治療 NRAS 突變 (NRASm) 黑色素瘤、RAS Q61X 實體瘤和其他 RAS/MAPK 通路驅動腫瘤患者。
公司簡介
公司代碼ERAS
公司名稱Erasca Inc
上市日期Jul 15, 2021
CEODr. Jonathan E. Lim, M.D.
員工數量103
證券類型Ordinary Share
年結日Jul 15
公司地址3115 Merryfield Row
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92121
電話18584656511
網址https://www.erasca.com/
公司代碼ERAS
上市日期Jul 15, 2021
CEODr. Jonathan E. Lim, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
21.17K
+37.11%
Dr. Shannon R. Morris, M.D., Ph.D.
Dr. Shannon R. Morris, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
--
--
Dr. Valerie Harding-Start, Ph.D.
Dr. Valerie Harding-Start, Ph.D.
Independent Director
Independent Director
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Independent Director
Independent Director
--
--
Dr. Michael David Varney, Ph.D.
Dr. Michael David Varney, Ph.D.
Director, Chair of Research and Development and Scientific Advisory Board member
Director, Chair of Research and Development and Scientific Advisory Board member
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
19.46M
--
Mr. Alexander W. (Alex) Casdin
Mr. Alexander W. (Alex) Casdin
Independent Director
Independent Director
667.72K
--
Dr. James Arthur Bristol
Dr. James Arthur Bristol
Lead Independent Director
Lead Independent Director
207.50K
--
Mr. Ebun S. Garner, J.D.
Mr. Ebun S. Garner, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
21.17K
+37.11%
Dr. Shannon R. Morris, M.D., Ph.D.
Dr. Shannon R. Morris, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David M. Chacko, M.D.
Dr. David M. Chacko, M.D.
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
7.97%
Lim (Jonathan E)
6.87%
T. Rowe Price Investment Management, Inc.
6.10%
VR Adviser, LLC
5.72%
BlackRock Institutional Trust Company, N.A.
4.96%
Other
68.38%
持股股東
持股股東
佔比
Frazier Life Sciences Management, L.P.
7.97%
Lim (Jonathan E)
6.87%
T. Rowe Price Investment Management, Inc.
6.10%
VR Adviser, LLC
5.72%
BlackRock Institutional Trust Company, N.A.
4.96%
Other
68.38%
股東類型
持股股東
佔比
Investment Advisor
26.42%
Hedge Fund
20.60%
Venture Capital
20.54%
Private Equity
7.97%
Individual Investor
7.35%
Investment Advisor/Hedge Fund
7.02%
Corporation
4.34%
Research Firm
1.43%
Bank and Trust
0.23%
Other
4.10%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
308
274.06M
96.74%
-34.98M
2025Q1
317
274.49M
97.07%
-35.76M
2024Q4
322
280.04M
99.05%
-35.03M
2024Q3
313
281.15M
102.27%
+61.97K
2024Q2
303
252.04M
113.79%
+64.87M
2024Q1
280
120.99M
80.07%
-2.11M
2023Q4
270
117.59M
77.97%
+472.06K
2023Q3
257
122.33M
82.97%
-7.99M
2023Q2
252
125.95M
86.10%
-5.27M
2023Q1
244
129.53M
89.86%
-627.20K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Frazier Life Sciences Management, L.P.
22.58M
7.97%
+3.18M
+16.42%
Mar 31, 2025
Lim (Jonathan E)
19.46M
6.87%
--
--
Apr 15, 2025
T. Rowe Price Investment Management, Inc.
17.29M
6.1%
+581.82K
+3.48%
Mar 31, 2025
VR Adviser, LLC
16.22M
5.72%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.05M
4.96%
-167.68K
-1.18%
Mar 31, 2025
Logos Global Management LP
13.00M
4.59%
+500.00K
+4.00%
Mar 31, 2025
City Hill Ventures, LLC
12.90M
4.55%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
12.69M
4.48%
+53.52K
+0.42%
Mar 31, 2025
Suvretta Capital Management, LLC
12.32M
4.35%
--
--
Mar 31, 2025
Novartis Pharma AG
12.31M
4.34%
--
--
Dec 31, 2024
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.75%
ALPS Medical Breakthroughs ETF
0.24%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Russell 2000 Value ETF
0.02%
Fidelity Enhanced Small Cap ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares US Small-Cap Equity Factor ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.75%
ALPS Medical Breakthroughs ETF
佔比0.24%
iShares Micro-Cap ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
iShares Russell 2000 Value ETF
佔比0.02%
Fidelity Enhanced Small Cap ETF
佔比0.02%
iShares Biotechnology ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
iShares US Small-Cap Equity Factor ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
